{"id":66337,"date":"2026-05-26T14:51:31","date_gmt":"2026-05-26T06:51:31","guid":{"rendered":"https:\/\/flcube.com\/?p=66337"},"modified":"2026-05-26T14:51:32","modified_gmt":"2026-05-26T06:51:32","slug":"changchun-high-new-technology-secures-nmpa-clinical-filing-acceptance-for-gensci144-slc6a19-inhibitor-in-chronic-kidney-disease","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66337","title":{"rendered":"Changchun High &amp; New Technology Secures NMPA Clinical Filing Acceptance for GenSci144 SLC6A19 Inhibitor in Chronic Kidney Disease"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Changchun High &amp; New Technology Industries (Group) Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/000661:SHE\">SHE: 000661<\/a>) announced that the <strong>National Medical Products Administration (NMPA)<\/strong> has <strong>accepted for review<\/strong> its clinical trial application for <strong>GenSci144<\/strong>, an <strong>oral SLC6A19 inhibitor<\/strong>, for the treatment of <strong>chronic kidney disease (CKD)<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Filing Status<\/strong><\/td><td>Clinical trial application accepted for review<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>GenSci144 \u2013 oral SLC6A19 inhibitor<\/td><\/tr><tr><td><strong>Primary Indication<\/strong><\/td><td>Chronic kidney disease (CKD) \u2013 all types<\/td><\/tr><tr><td><strong>Secondary Indication<\/strong><\/td><td>Phenylketonuria (PKU) \u2013 previously accepted<\/td><\/tr><tr><td><strong>Filing Date<\/strong><\/td><td>May 2026<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Clinical trial initiation upon final approval<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-novel-mechanism-of-action-amp-therapeutic-rationale\" class=\"wp-block-heading\">Novel Mechanism of Action &amp; Therapeutic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target:<\/strong> <strong>SLC6A19 transporter<\/strong> \u2013 neutral amino acid transporter in renal tubules and small intestine<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Inhibits (re)absorption of neutral amino acids, reducing metabolic overload in proximal tubules<\/li>\n\n\n\n<li><strong>Physiological Effects:<\/strong><\/li>\n\n\n\n<li><strong>Activates glomerulotubular feedback<\/strong> \u2013 natural kidney protective mechanism<\/li>\n\n\n\n<li><strong>Mimics low-protein diet benefits<\/strong> \u2013 established therapeutic approach for CKD<\/li>\n\n\n\n<li><strong>Improves intrarenal metabolic disorders<\/strong> \u2013 addresses root cause of progression<\/li>\n\n\n\n<li><strong>Reduces inflammation and fibrosis<\/strong> \u2013 key drivers of kidney function decline<\/li>\n\n\n\n<li><strong>Therapeutic Advantage:<\/strong> <strong>Distinct from existing therapies<\/strong> (RAAS inhibitors, SGLT2 inhibitors)<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-competitive-differentiation-in-ckd-landscape\" class=\"wp-block-heading\">Competitive Differentiation in CKD Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Therapy Class<\/th><th>Mechanism<\/th><th>Limitations<\/th><th>GenSci144 Advantage<\/th><\/tr><\/thead><tbody><tr><td><strong>RAAS Inhibitors<\/strong><\/td><td>Block renin-angiotensin-aldosterone system<\/td><td>Hyperkalemia risk, limited efficacy in advanced CKD<\/td><td><strong>Novel target<\/strong>, complementary mechanism<\/td><\/tr><tr><td><strong>SGLT2 Inhibitors<\/strong><\/td><td>Block glucose reabsorption in proximal tubule<\/td><td>Genital infections, volume depletion, limited in low eGFR<\/td><td><strong>Different pathway<\/strong>, potentially broader applicability<\/td><\/tr><tr><td><strong>GenSci144 (SLC6A19i)<\/strong><\/td><td><strong>Inhibit neutral amino acid reabsorption<\/strong><\/td><td><strong>First-in-class<\/strong> \u2013 safety profile to be established<\/td><td><strong>Universal applicability across CKD types<\/strong>, combination potential<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-clinical-development-strategy-amp-market-opportunity\" class=\"wp-block-heading\">Clinical Development Strategy &amp; Market Opportunity<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Program Element<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Target Population<\/strong><\/td><td><strong>All types of CKD patients<\/strong> \u2013 estimated 120-150 million in China<\/td><\/tr><tr><td><strong>Combination Potential<\/strong><\/td><td>Compatible with RAAS inhibitors and SGLT2 inhibitors for synergistic effects<\/td><\/tr><tr><td><strong>Dosing Regimen<\/strong><\/td><td>Oral administration \u2013 convenient for chronic disease management<\/td><\/tr><tr><td><strong>Regulatory Pathway<\/strong><\/td><td>Category 1 innovative drug designation likely given novel mechanism<\/td><\/tr><tr><td><strong>Development Timeline<\/strong><\/td><td>Phase I expected to initiate 2026-2027; multiple indications leverage same safety database<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The acceptance of clinical filings for both <strong>CKD and PKU<\/strong> demonstrates the versatility of SLC6A19 inhibition across different disease states involving amino acid metabolism.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-positioning\" class=\"wp-block-heading\">Market Impact &amp; Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CKD Market Size:<\/strong> China&#8217;s CKD market estimated at \u00a530-50 billion annually with significant unmet need for disease-modifying therapies<\/li>\n\n\n\n<li><strong>Treatment Gap:<\/strong> Current therapies slow but don&#8217;t halt progression; GenSci144 addresses fundamental metabolic dysfunction<\/li>\n\n\n\n<li><strong>Commercial Advantage:<\/strong> First-mover in SLC6A19 inhibition class; potential for premium pricing and rapid market adoption<\/li>\n\n\n\n<li><strong>Global Implications:<\/strong> Success in China could facilitate international development given universal CKD pathophysiology<\/li>\n\n\n\n<li><strong>Portfolio Diversification:<\/strong> Expands Changchun High &amp; New Technology&#8217;s presence beyond traditional biologics into novel small molecule therapeutics<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical development, and commercial expectations for GenSci144. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, safety findings, competitive dynamics, and market adoption.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8GenSci144\u7247\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8GenSci144\u7247\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-12661978-8cfe-447c-b2ce-04f37309160d\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8GenSci144\u7247\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a.pdf\">\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8GenSci144\u7247\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8GenSci144\u7247\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-12661978-8cfe-447c-b2ce-04f37309160d\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Changchun High &amp; New Technology Industries (Group) Inc. (SHE: 000661) announced that the National Medical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[2929,90,1171],"class_list":["post-66337","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-changchun-high-new-technology-industries","tag-clinical-trial-filings","tag-she-000661"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Changchun High &amp; New Technology Secures NMPA Clinical Filing Acceptance for GenSci144 SLC6A19 Inhibitor in Chronic Kidney Disease - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Changchun High &amp; New Technology Industries (Group) Inc. (SHE: 000661) announced that the National Medical Products Administration (NMPA) has accepted for review its clinical trial application for GenSci144, an oral SLC6A19 inhibitor, for the treatment of chronic kidney disease (CKD).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66337\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Changchun High &amp; New Technology Secures NMPA Clinical Filing Acceptance for GenSci144 SLC6A19 Inhibitor in Chronic Kidney Disease\" \/>\n<meta property=\"og:description\" content=\"Changchun High &amp; New Technology Industries (Group) Inc. (SHE: 000661) announced that the National Medical Products Administration (NMPA) has accepted for review its clinical trial application for GenSci144, an oral SLC6A19 inhibitor, for the treatment of chronic kidney disease (CKD).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66337\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-26T06:51:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-26T06:51:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66337#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66337\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Changchun High &amp; New Technology Secures NMPA Clinical Filing Acceptance for GenSci144 SLC6A19 Inhibitor in Chronic Kidney Disease\",\"datePublished\":\"2026-05-26T06:51:31+00:00\",\"dateModified\":\"2026-05-26T06:51:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66337\"},\"wordCount\":477,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Changchun High &amp; New Technology Industries\",\"Clinical trial filings\",\"SHE: 000661\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66337#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66337\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66337\",\"name\":\"Changchun High &amp; New Technology Secures NMPA Clinical Filing Acceptance for GenSci144 SLC6A19 Inhibitor in Chronic Kidney Disease - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-26T06:51:31+00:00\",\"dateModified\":\"2026-05-26T06:51:32+00:00\",\"description\":\"Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that the National Medical Products Administration (NMPA) has accepted for review its clinical trial application for GenSci144, an oral SLC6A19 inhibitor, for the treatment of chronic kidney disease (CKD).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66337#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66337\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66337#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Changchun High &amp; New Technology Secures NMPA Clinical Filing Acceptance for GenSci144 SLC6A19 Inhibitor in Chronic Kidney Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Changchun High &amp; New Technology Secures NMPA Clinical Filing Acceptance for GenSci144 SLC6A19 Inhibitor in Chronic Kidney Disease - Insight, China&#039;s Pharmaceutical Industry","description":"Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that the National Medical Products Administration (NMPA) has accepted for review its clinical trial application for GenSci144, an oral SLC6A19 inhibitor, for the treatment of chronic kidney disease (CKD).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66337","og_locale":"en_US","og_type":"article","og_title":"Changchun High &amp; New Technology Secures NMPA Clinical Filing Acceptance for GenSci144 SLC6A19 Inhibitor in Chronic Kidney Disease","og_description":"Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that the National Medical Products Administration (NMPA) has accepted for review its clinical trial application for GenSci144, an oral SLC6A19 inhibitor, for the treatment of chronic kidney disease (CKD).","og_url":"https:\/\/flcube.com\/?p=66337","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-26T06:51:31+00:00","article_modified_time":"2026-05-26T06:51:32+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66337#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66337"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Changchun High &amp; New Technology Secures NMPA Clinical Filing Acceptance for GenSci144 SLC6A19 Inhibitor in Chronic Kidney Disease","datePublished":"2026-05-26T06:51:31+00:00","dateModified":"2026-05-26T06:51:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66337"},"wordCount":477,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Changchun High &amp; New Technology Industries","Clinical trial filings","SHE: 000661"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66337#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66337","url":"https:\/\/flcube.com\/?p=66337","name":"Changchun High &amp; New Technology Secures NMPA Clinical Filing Acceptance for GenSci144 SLC6A19 Inhibitor in Chronic Kidney Disease - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-26T06:51:31+00:00","dateModified":"2026-05-26T06:51:32+00:00","description":"Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that the National Medical Products Administration (NMPA) has accepted for review its clinical trial application for GenSci144, an oral SLC6A19 inhibitor, for the treatment of chronic kidney disease (CKD).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66337#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66337"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66337#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Changchun High &amp; New Technology Secures NMPA Clinical Filing Acceptance for GenSci144 SLC6A19 Inhibitor in Chronic Kidney Disease"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66337","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66337"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66337\/revisions"}],"predecessor-version":[{"id":66340,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66337\/revisions\/66340"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66337"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66337"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66337"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}